March 28, 2014
1 min read

Debridement offers no advantage in treating microsporidial keratoconjunctivitis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Corneal debridement showed no distinct advantage in resolving corneal lesions and improving vision in eyes treated for microsporidial keratoconjunctivitis, a study found.

The prospective, double-masked, randomized study included 120 patients with clinical features indicative of microsporidial superficial keratoconjunctivitis.

Fifty-eight patients underwent debridement, and 62 patients underwent conjunctival swabbing. All patients received ocular lubricants.

The primary outcome measure was time to full resolution of clinical signs and symptoms. Secondary outcome measures were final Snellen visual acuity and residual corneal side effects and/or scarring. Patients were examined at 1, 3 and 7 days and every week until clinical signs and symptoms resolved.

Mean time to resolution of corneal lesions was 5.7 days in the debridement group and 5.9 days in the swabbing group. Final visual acuity was 0.14 in the debridement group and 0.18 in the swabbing group. Scarring was identified in 34.3% of patients in the debridement group and 28.6% of patients in the swabbing group. These differences were not statistically significant.

Disclosure: The authors have no relevant financial disclosures.